Skip to main content

Delivering therapies to transform the lives of patients through recombinase technology

Accessing a seamless approach to treating severe disease

About Us

We are a team of experienced drug developers dedicated to correcting the genetic cause of disease by making large edits to the human genome using the unparalleled precision and efficiency of programmable recombinases. Seamless Therapeutics is applying programmable recombinase technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

Seamless is developing a unique approach to gene editing using programmable recombinases to address genetic disease. Our technology Seamlessly performs large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. By unlocking programmable recombinases, Seamless has the potential to transform patient outcomes across a broad range of diseases.

Our Strategic Focus

Leadership

An esteemed and accomplished leadership team drives Seamless Therapeutics. Together with their experienced Board of Directors, they pursue a shared vision to transform the gene-editing landscape.

Anne-Kristin Heninger, PhD
Head of Operations & Managing Director, Dresden, Germany

Anne-Kristin Heninger is a co-founder of Seamless Therapeutics and serves as Head of Operations and Managing Director in Germany. Dr Heninger played a key role in developing the business and financial strategies for Seamless Therapeutics, while also successfully securing IP rights for the company. Dr Heninger began her work in genome editing at the Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden. She holds a BSc in Biochemistry and Microbiology from the University of Washington in Seattle and earned her PhD in Immunology at the Dresden University of Technology.

Felix Lansing is a scientific co-founder and currently serves as the Chief Technology Officer. The foundation of the technology used at Seamless originated from Dr Lansing’s research and discovery of programmable recombinases during his PhD studies at Dresden University of Technology. He is an author of many peer-reviewed publications, an inventor on 7 patents, and is dedicated to leveraging his expertise to address how programmable recombinases can be applied to solve genetic disease and improve the lives of patients. He earned his BSc in Molecular Biology from Bielefeld University, his MSc in Regenerative Biology and Medicine and his PhD in genetics and genome engineering at the Dresden University of Technology.

Felix Lansing, PhD
Co-Founder & CTO

Board of Directors

Albert Seymour, PhD
Board Director

Dmitrij Hristodorov, PhD
Board Director

Varun Gupta
Board Director

Scientific Advisory Board

Prof. Frank Buchholz, PhD
Chair of Scientific Advisory Board

Investors

Seamless Therapeutics is supported by leading life-science investors.

Careers

We are a dynamic team pioneering a groundbreaking new gene-editing approach with a deep understanding of recombinases and their potential in repairing genes that cause serious diseases. We foster creativity, leadership, and teamwork, and empower our people to make decisions and contribute positively to our goals. We also offer a supportive environment for colleagues to learn from each other, tackle challenges together, and celebrate our achievements.

GO TO CAREER PAGE
de_DEDeutsch
Powered by TranslatePress